Advocating for access to and reimbursement for biosimilars.
2025 · 3rd Quarter (July 1 - Sep 30)
INFUSION PROVIDERS ALLIANCE
Filed by THE MCMANUS GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2025
- Income
- $90,000.00
- Expenses
- Not reported
- Registrant
- THE MCMANUS GROUP
- Filing UUID
- 8ac990b5-9333-4347-8e94-5e02e12118ec
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).
Literal federal measure citations: H.R. 4299
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.